Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Decibel Therapeutics

Decibel Therapeutics
2015 FOUNDED
PRIVATE STATUS
Series C LATEST DEAL TYPE
$55.1M LATEST DEAL AMOUNT
11 INVESTORS
Description

Developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 1325 Boylston Street
  • Suite 500
  • Boston, MA 02215
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Decibel Therapeutics’s full profile, request a free trial.

Decibel Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 19-Jun-2018 $55.1M 00000 00000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 06-Jul-2017 0000 0000 00000 Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 15-Oct-2015 $52M $52M 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Decibel Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00.00 00 00 00 00 00.000
Series B 00,000,000 00.000000 00.00 00 00 00 00 0.000
Series A 57,758,734 $0.001000 $0.08 $1 $1 1x $1 44.43%
To view this company’s complete Cap Table, request access »

Decibel Therapeutics Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Acousia Therapeutics Venture Capital-Backed Tübingen, Germany 000.00 00000000000 000.00
000000000 00000000 Venture Capital-Backed Woburn, MA 00 0000 00000000000 0000
000000 00000000000 Venture Capital-Backed Brisbane, CA 0 000.00 00000000000 000.00
000000 00000000000 Venture Capital-Backed Amsterdam, Netherlands 00.000 00000000000 00.000
00000000 000000000 Venture Capital-Backed London, United Kingdom 00 000.00 000000000000 000.00
To view this company’s complete list of competitors, request access »

Decibel Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Bessemer Venture Partners Venture Capital Minority 000 0000 000000 0
Foresite Capital Management Growth/Expansion Minority 000 0000 000000 0
Koa Labs Accelerator/Incubator Minority 000 0000 000000 0
Schroder Adveq Management Asset Manager Minority 000 0000 000000 0
S-Cubed Capital Family Office Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Decibel Therapeutics Executive Team (15)

Name Title Board
Seat
Contact
Info
Steven Holtzman Chief Executive Officer, President and Board Member
Paula Cobb Chief Operating Officer
Shin-San Michael Su Ph.D Chief Scientific Officer
John Keilty Chief Data Sciences Officer
Leslie Shinobu MD Chief of Translational Research

3 Former Executives

You’re viewing 5 of 15 executives. Get the full list »

Decibel Therapeutics Board Members (11)

Name Representing Role Since Contact
Info
Anthony Philippakis MD GV Board Member 000 0000
Craig Muir Third Rock Ventures Board Member 000 0000
Gabriel Corfas Ph.D Decibel Therapeutics Co-Founder & Member of Scientific Advisory Board 000 0000
George Scangos Ph.D Self Chairman 000 0000
Jeffrey Jonas MD Self Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 11 board members. Get the full list »